REGN-EB3
E106452
REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
All labels observed (1)
| Label | Occurrences |
|---|---|
| REGN-EB3 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T903525 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: REGN-EB3 Context triple: [2018–2020 Kivu Ebola epidemic in the Democratic Republic of the Congo, treatmentUsed, REGN-EB3]
-
A.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
D.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: REGN-EB3 Target entity description: REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
-
A.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
D.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
Ebola virus disease treatment
ⓘ
monoclonal antibody cocktail ⓘ therapeutic antibody ⓘ |
| administrationSetting | hospital ⓘ |
| antibodyClass | IgG1 ⓘ |
| antibodyType | human monoclonal antibody ⓘ |
| ATCCode | J06BD03 ⓘ |
| brandName | Inmazeb ⓘ |
| clinicalEffect | reduction of mortality in Ebola virus disease ⓘ |
| clinicalTrialOutcome | significant reduction in death compared with control therapy ⓘ |
| clinicalTrialType | randomized controlled trial ⓘ |
| combinationType | fixed-dose combination of three antibodies ⓘ |
| comparisonTherapy | ZMapp in clinical trials ⓘ |
| compositionFeature | three non-competing monoclonal antibodies ⓘ |
| contraindicationNote | not recommended for prophylactic use ⓘ |
| developer | Regeneron Pharmaceuticals ⓘ |
| dosingRegimen | single-course intravenous administration ⓘ |
| FDAApprovalType | Biologics License Application approved ⓘ |
| FDAApprovalYear | 2020 ⓘ |
| geographicUse | outbreak settings in Africa ⓘ |
| hasComponent |
atoltivimab
ⓘ
maftivimab ⓘ odesivimab ⓘ |
| indication |
treatment of Ebola virus disease in adults
ⓘ
treatment of Ebola virus disease in pediatric patients ⓘ treatment of infection caused by Zaire ebolavirus ⓘ |
| mechanismOfAction |
inhibition of viral entry into host cells
ⓘ
neutralization of Ebola virus glycoprotein ⓘ |
| origin | developed using Regeneron VelocImmune platform ⓘ |
| pharmacologicalClass | antiviral monoclonal antibody ⓘ |
| regulatoryStatus | approved by U.S. FDA ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| safetyProfile | generally well tolerated in clinical trials ⓘ |
| storageCondition | refrigerated ⓘ |
| targetDisease | Ebola virus disease ⓘ |
| targetMolecule | Ebola virus glycoprotein GP ⓘ |
| targetPathogen | Zaire ebolavirus ⓘ |
| therapeuticArea |
infectious disease
ⓘ
virology ⓘ |
| treatmentPhase | acute Ebola virus infection ⓘ |
| trialPopulation | patients with confirmed Zaire ebolavirus infection ⓘ |
| WHORelevance | treatment option for Ebola virus disease outbreaks ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: REGN-EB3 Description of subject: REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.